drugset
drugset / Trial / NCT03644953

Hydroxyurea and Transfusion

NCT03644953 ↗

Phase 2 Completed 14 enrolled Children's National Research Institute
NaSingle-groupOpen-labelTreatment

Summary

This study will prospectively investigate the feasibility, safety, and transfusion requirements of adding hydroxyurea to simple chronic transfusions for patients with sickle cell anemia already on chronic transfusions.

Timeline

Start
2018-10-30
Primary completion
2021-07-01
Completion
2021-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxyurea Other / unclassified 20 mg/kg —

Indications

sickle cell disease